Search results with tag "Zyprexa"
1. ZYPREXA IM 2. QUALITATIVE AND QUANTITATIVE …
www.medsafe.govt.nz4.4 Special warnings and precautions for use and 5.1 Pharmacodynamic properties). Instructions for use/handling – ZYPREXA IM vial • ZYPREXA IM should be reconstituted only with sterile water for …
HIGHLIGHTS OF PRESCRIBING INFORMATION • Efficacy ...
pi.lilly.com• Efficacy was established in three 1-day trials in adults. (14.3) As ZYPREXA and Fluoxetine in Combination forthe: • Treatment of depressive episodes associated with bipolarI disorder. (1.5) • Efficacy was established with Symbyax (olanzapine and fluoxetine in combination); refer to the product label for Symbyax.
NIHS 医薬品安全性情報 Vol.13 No.10 201505//21
www.nihs.go.jp医薬品安全性情報Vol.13 No.10（2015/05/21） 3 . データの概要. 2. 人の患者が[‘ Zyprexa Relprevv’]の筋肉内投与を受けて数日後に原因不明で死亡したこと，
NEW ZEALAND DATASHEE T - Medsafe
www.medsafe.govt.nzElderly patients ZYPREXA RELPREVV has not been systematically studied in elderly patients (65 years and over), hepatically or renally impaired patients.
QUALITATIVE AND QUANTITATIVE COMPOSITION
www.medsafe.govt.nzAcute mania associated with bipolar disorder The recommended starting dose for ZYPREXA is 10 or 15 mg administered once a day as monotherapy or 10 mg administered ...
Please see the Prescribing Information ... - …
www.zyprexarelprevvprogram.com6 ZYPREXA RELPREVV is a combination of olanzapine and pamoic acid in the form of a crystalline salt, which is insoluble in water but has very low solubility in muscle.
ZYPREXA and Zydis - Medsafe
www.medsafe.govt.nzNZ ZYPREXA® & ZYPREXA Zydis v6.1 1 ZYPREXA® and ZYPREXA®Zydis® olanzapine Consumer Medicine Information . What is in this leaflet . This leaflet is …
ZYPREXA RELPREVV Patient Care Program Instructions …
www.zyprexarelprevvprogram.comIntroduction to the ZYPREXA RElPREvv Patient Care Program Patient Care Program Overview ZYPREXA RElPREVV is the long-acting intramuscular formulation of olanzapine indicated for treatment